{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.0","upperLimit":"57.0","value":"46.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"description":"3 yr Overall Survival estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan\\* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.\n\nNote: \\*Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.\n\nfludarabine phosphate: Given IV\n\nmelphalan: Given IV\n\ntotal-body irradiation: Undergo total-body irradiation\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation\n\nanti-thymocyte globulin: Given IV","id":"OG000","title":"Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)"}],"paramType":"NUMBER","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"Up to 4.5 years","title":"3 yr Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}